Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

22.61
-0.3600-1.57%
Post-market: 22.610.00000.00%18:21 EDT
Volume:366.20K
Turnover:8.29M
Market Cap:1.64B
PE:-37.39
High:23.03
Open:22.73
Low:22.33
Close:22.97
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx

Reuters
·
13 Mar

Kiniksa Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
13 Mar

Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target

MT Newswires Live
·
13 Mar

BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty

Reuters
·
13 Mar

Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock

Zacks
·
05 Mar

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Zacks
·
04 Mar

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now?

Insider Monkey
·
03 Mar

US High Growth Tech Stocks With Strong Potential

Simply Wall St.
·
01 Mar

Evercore ISI Remains a Buy on Kiniksa Pharmaceuticals (KNSA)

TIPRANKS
·
28 Feb

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
25 Feb

Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases

MT Newswires Live
·
25 Feb

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M

MT Newswires Live
·
25 Feb

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss

MT Newswires Live
·
25 Feb

Kiniksa Expects 2025 Arcalyst Net Product Revenue Of Between $560M-$580M

Benzinga
·
25 Feb

Kiniksa Pharmaceuticals Q4 2024 GAAP EPS $(0.12) May Not Be Comparable To $0.04 Estimate, Sales $122.54M Miss $123.38M Estimate

Benzinga
·
25 Feb

Kiniksa : Has Exercised Its Right to Terminate Its Exclusive License Agreement for Mavrilimumab With Medimmune

THOMSON REUTERS
·
25 Feb